Rucaparib (AG 014699) is a PARP inhibitor being investigated as a potential anti-cancer agent. Rucaparib is the first-in-class clinical candidate targeting the DNA repair enzyme poly-ADPribose polymerase-1 (PARP-1), and was first synthesised as part of a collaboration between scientists working in Northern Institute of Cancer Research and Medical School of Newcastle University, alongside Agouron Pharmaceuticals (San Diego). It is being developed by Clovis Oncology.

CAS：283173-50-2
中文别名：8-氟-1,3,4,5-四氢-2-[4-[(甲基氨基)甲基]苯基]-6H-吡咯并[4,3,2-EF][2]苯并氮杂卓-6-酮;
英文别名：8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one;6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl];Kinome_3180;RUCAPARIB;UNII-8237F3U7EH;8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one;
分子式：C19H18FN3O
分子量：323.364
精确质量：323.143
Psa：56.92
Logp：3.699

UNII：8237F3U7EH

密度：1.281 g/cm3
沸点：625.248ºC at 760 mmHg
闪点：331.938ºC

海关编码：2933990090